A large investigation reports that more than half of patients receiving lifesaving cellular therapies experience orthostatic hypotension—a dangerous blood pressure drop upon standing—within their first month. The study’s central clinical takeaway is that hidden hemodynamic instability may be more common than clinicians recognize during early treatment follow-up. For biotech sponsors and care teams, the result is a prompt to revisit monitoring protocols around standing blood pressure, symptom reporting, and supportive management. Even without the full dataset in the brief, the fact that this appears across “one of the largest investigations of its kind” suggests the signal is robust enough to influence standard-of-care surveillance. Operationally, the finding also raises questions for trial design: whether risk stratification and adverse event capture for orthostatic symptoms should be more granular, particularly during the first month when the majority of cases emerge.